Page 374 - Read Online

Page 14 of 14 Pereira et al. J Cancer Metastasis Treat 2018;4:30 I http://dx.doi.org/10.20517/2394-4722.2018.13

pegylated recombinant human hyaluronidase (PEGPH20). Curr Oncol Rep 2017;19:47.
96. Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, Braiteh F, Ritch PS, Zalupski MM, Bahary N, Oberstein PE,
Wang-Gillam A, Wu W, Chondros D, Jiang P, Khelifa S, Pu J, Aldrich C, Hendifar AE. HALO 202: Randomized phase II study of
PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients with untreate, metastatic pancreatic ductal adenocarcinoma (mPDA).
J Clin Oncol 2017;35 suppl:abstr4008.
97. de Geus, SWL, Eskander, MF, Kasumova GG, Ng SC, Kent TS, Mancias JD, Callery MP, Mahadevan A, Tseng JF. Stereotactic body
radiotherapy for unresected pancreatic cancer: a nationwide review. Cancer 2017;123:4158-67.
98. Zhong J, Patel K, Switchenko J, Cassidy RJ, Hall WA, Gillespie T, Patel PR, Kooby D, Landry J. Outcomes for patients with locally
advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.
Cancer 2017;123:3486-93.
99. Sugawara A, Kunieda E. Effect of adjuvant radiotherapy on survival in resected pancreatic cancer: a propensity score surveillance,
epidemiology, and end results database analysis. J Surg Oncol 2014;110:960-6.
100. Baschnagel A, Shah C, Margolis J, Nadeau L, Stein J, Jury R, Robertson JM. Survival after chemoradiation in resected pancreatic
cancer: the impact of adjuvant gemcitabine. Int J Radiat Oncol Biol Phys 2012;83:E331-5.
101. Ng SP, Herman JM. Stereotactic radiotherapy and particle therapy for pancreatic cancer. Cancers (Basel) 2018;10:E75.
102. Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouché O, Shannon J, André T, Mineur L,
Chibaudel B, Bonnetain F, Louvet C; LAP07 Trial Group. Effect of chemoradiotherapy vs chemotherapy on survival in patients with
locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without ErlotinibThe LAP07 randomized clinical
trial. JAMA 2016;315:1844-53.
103. Huguet F, André T, Hammel P, Artru P, Balosso J, Selle F, Deniaud-Alexandre E, Ruszniewski P, Touboul E, Labianca R, de Gramont
A, Louvet C. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in
GERCOR phase II and III studies. J Clin Oncol 2007;25:326-31.
104. Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, Delclos ME, Gould MS, Evans DB, Wolff RA, Crane CH.
Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative
chemoradiation therapy. Cancer 2007;110:47-55.